Skip to main content
Default Image

The Case for a Public Option for the Drug Industry

Under siege from thousands of lawsuits from federal, state, and local governments for its role in the deadly opioid addiction crisis, drug manufacturer Purdue Pharma reached a tentative settlement with some of the plaintiffs last week. In the deal, Purdue would transform itself through the bankruptcy process from a typical, profit-chasing drugmaker into a “public beneficiary company.” The proposition raises an important question: If plaintiffs are open to the idea of turning Purdue into a public trust run by appointees of a federal bankruptcy judge—one that would distribute its profits to state and local governments—why not take one more step? Why not create the beginnings of a network of public pharmaceutical companies like those that already exists in such countries as Sweden, Brazil, and Thailand?

Publication date: 2019-09-15
Parent publication: New Republic
Publication URL: https://newrepublic.com/article/155071/case-public-option-drug-industry-purdue-pharma-settlement-bankruptcy

More related work

March 19, 2020
Default Image

Protect the vulnerable, advance the democratic economy: Our statement on the COVID-19 crisis

We are in a period of breakdown, in which all that is wrong with the current system is now being laid bare. Rather than rebuild what we now clearly see should never have been, we must lead the construction out of this crisis of something new.

read more
March 18, 2020
Default Image

HAN Public Comments on Fair Housing Act Proposed Changes

The Healthcare Anchor Network submitted public comments to the Department of Housing and Urban Development (HUD), expressing our opposition to HUD’s proposed changes to the 2015 Affirmatively Furthering Fair Housing rule.

read more
March 17, 2020
An array of prescription medications on shelves

Online press briefing: Vaccines—The COVID-19 Case for Public Pharmaceutical Research and Development

Leading experts believe that it is the government’s responsibility to ensure widespread access to safe and effective vaccines that are developed with taxpayer money. In this virtual press briefing, hear why the U.S. government should develop and manufacture vaccines and other essential medicines so that we get the medicines we need, when we need them and at prices we can afford.

read more